# Intellia Therapeutics to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-participate-in-upcoming-investor-conferences
Ticker: NTLA
Company: Intellia
Source: Intellia
Published: 2026-05-05 11:30 EST
Original Source URL: https://ir.intelliatx.com
## Summary

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats

## Article Body
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats
## Recent Company News
- 2026-06-01 11:30 EST — [Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-report-additional-phase-3-haelo-data-for-lonvoguran-ziclumeran-lonvo-z-in-late-breaking-oral-presentation-at-eaaci-2026) — Source: Intellia
- 2026-05-11 11:30 EST — [Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2026-financial-results-and-business-updates) — Source: Intellia
- 2026-05-05 11:30 EST — [Intellia Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Intellia
- 2026-05-01 20:01 EST — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Intellia
- 2026-04-29 11:00 EST — [Intellia Therapeutics Announces Pricing of Public Offering of Common Stock](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-announces-pricing-of-public-offering-of-common-stock) — Source: Intellia
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)